Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AFM 13

Drug Profile

AFM 13

Alternative Names: AFM-13; Anti-CD30 anti-CD16A antibody - Affimed Therapeutics; TandAb AFM13

Latest Information Update: 12 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Affimed Therapeutics
  • Developer Affimed Therapeutics; Merck AG; The Leukemia & Lymphoma Society; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hodgkin's disease
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hodgkin's disease; Mycosis fungoides; Peripheral T-cell lymphoma
  • Phase I/II Cutaneous T-cell lymphoma

Most Recent Events

  • 05 Nov 2019 Phase-II clinical trials in Mycosis fungoides (Second-line therapy or greater) in USA (IV) (NCT04101331)
  • 05 Nov 2019 Phase-II clinical trials in Peripheral T-cell lymphoma (Second-line therapy or greater) in USA (IV) (NCT04101331)
  • 16 Sep 2019 Phase-II clinical trials in Mycosis fungoides (Second-line therapy or greater) in Spain (IV) (EudraCT2019-001003-20)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top